A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Inclusion Criteria

• •Documented lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1 activation, based on standard diagnostic cytogenetic evaluation performed locally, before signing informed consent for this study.
• •Eligible subjects must:
• •* Have relapsed after stem cell transplantation or after other disease modifying therapy, OR
• •* Not be current candidates for stem cell transplantation or other disease modifying therapies.
• •Note: All relapsed/refractory subjects must have evidence of either cytogenetic or hematological disease and have no evidence of residual toxicity (eg, graft-versus-host disease requiring treatment).
• •Life expectancy ≥ 12 weeks.
• •Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.